SK283729B6 - Kryštály P1, P4-di(uridín-5')-tetrafosfátu alebo kryštály jeho soli, spôsob ich výroby, kryštály tetrasodnej soli P1, P4-di(uridín-5')-tetrafosfátu a kryštály jej hydrátov - Google Patents

Kryštály P1, P4-di(uridín-5')-tetrafosfátu alebo kryštály jeho soli, spôsob ich výroby, kryštály tetrasodnej soli P1, P4-di(uridín-5')-tetrafosfátu a kryštály jej hydrátov Download PDF

Info

Publication number
SK283729B6
SK283729B6 SK440-2001A SK4402001A SK283729B6 SK 283729 B6 SK283729 B6 SK 283729B6 SK 4402001 A SK4402001 A SK 4402001A SK 283729 B6 SK283729 B6 SK 283729B6
Authority
SK
Slovakia
Prior art keywords
crystals
salt
uridine
ump
tetrafosphate
Prior art date
Application number
SK440-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK4402001A3 (en
Inventor
Hideaki Maeda
Toshio Yamada
Hiroshi Sato
Yutaka Noda
Original Assignee
Yamasa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Corporation filed Critical Yamasa Corporation
Publication of SK4402001A3 publication Critical patent/SK4402001A3/sk
Publication of SK283729B6 publication Critical patent/SK283729B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK440-2001A 1998-10-02 1999-10-01 Kryštály P1, P4-di(uridín-5')-tetrafosfátu alebo kryštály jeho soli, spôsob ich výroby, kryštály tetrasodnej soli P1, P4-di(uridín-5')-tetrafosfátu a kryštály jej hydrátov SK283729B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP28166398 1998-10-02
JP17068199 1999-06-17
PCT/JP1999/005415 WO2000020430A1 (fr) 1998-10-02 1999-10-01 Cristal de diuridine tetraphosphate ou sel correspondant et procede de fabrication

Publications (2)

Publication Number Publication Date
SK4402001A3 SK4402001A3 (en) 2001-11-06
SK283729B6 true SK283729B6 (sk) 2003-12-02

Family

ID=26493605

Family Applications (1)

Application Number Title Priority Date Filing Date
SK440-2001A SK283729B6 (sk) 1998-10-02 1999-10-01 Kryštály P1, P4-di(uridín-5')-tetrafosfátu alebo kryštály jeho soli, spôsob ich výroby, kryštály tetrasodnej soli P1, P4-di(uridín-5')-tetrafosfátu a kryštály jej hydrátov

Country Status (21)

Country Link
US (2) US6458946B1 (ja)
EP (1) EP1043329B1 (ja)
JP (2) JP3247685B2 (ja)
KR (1) KR100475008B1 (ja)
CN (2) CN100396692C (ja)
AT (1) ATE222920T1 (ja)
AU (1) AU747096C (ja)
BR (2) BRPI9917911B1 (ja)
CA (1) CA2345624C (ja)
CZ (1) CZ300402B6 (ja)
DE (1) DE69902624T2 (ja)
EA (2) EA003167B1 (ja)
ES (1) ES2183650T3 (ja)
HU (1) HU228681B1 (ja)
IL (1) IL142181A (ja)
MX (1) MXPA01003377A (ja)
NO (1) NO317305B1 (ja)
NZ (1) NZ510748A (ja)
PL (1) PL199434B1 (ja)
SK (1) SK283729B6 (ja)
WO (1) WO2000020430A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US7078391B2 (en) 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
AU767136B2 (en) * 1999-06-30 2003-10-30 Merck Sharp & Dohme Corp. Dinucleotide crystals
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
CN100363376C (zh) * 2006-06-12 2008-01-23 南京工业大学 一种5’-核苷三磷酸钠盐的结晶方法
CN107709345A (zh) * 2015-06-29 2018-02-16 雅玛山酱油株式会社 P1，p4‑二(尿苷5′）‑四磷酸晶体的保存方法
WO2018079503A1 (ja) 2016-10-25 2018-05-03 ヤマサ醤油株式会社 Ｐ１，ｐ４－ジ（ウリジン５'－）テトラホスフェートの精製方法
KR20180091689A (ko) * 2017-11-06 2018-08-16 주식회사 종근당 무정형 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
CN109021049B (zh) * 2018-06-14 2020-12-08 扬子江药业集团北京海燕药业有限公司 一种尿苷5′-二磷酸-苯并咪唑二钠的合成方法
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
CN1229114C (zh) * 1996-03-27 2005-11-30 印斯拜尔药品股份有限公司 用三磷酸尿苷和相关化合物治疗纤毛运动障碍的方法
US6319908B1 (en) * 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
NZ501696A (en) * 1997-07-25 2001-08-31 Inspire Pharmaceuticals Inc Method for large-scale production of sodium and ammonium salts of di(uridine 5')-tetraphosphate

Also Published As

Publication number Publication date
US20020156269A1 (en) 2002-10-24
MXPA01003377A (es) 2003-06-24
IL142181A (en) 2005-12-18
EA200200695A1 (ru) 2002-10-31
IL142181A0 (en) 2002-03-10
NO20011634L (no) 2001-05-30
JP3824894B2 (ja) 2006-09-20
CZ20011028A3 (cs) 2001-08-15
CN1502622A (zh) 2004-06-09
US6780988B2 (en) 2004-08-24
SK4402001A3 (en) 2001-11-06
NZ510748A (en) 2002-10-25
AU6000899A (en) 2000-04-26
EP1043329B1 (en) 2002-08-28
JP2002053590A (ja) 2002-02-19
NO317305B1 (no) 2004-10-04
CA2345624A1 (en) 2000-04-13
HU228681B1 (en) 2013-05-28
ES2183650T3 (es) 2003-03-16
CA2345624C (en) 2006-12-05
EA003167B1 (ru) 2003-02-27
BRPI9917911B1 (pt) 2016-08-23
EA004513B1 (ru) 2004-04-29
EP1043329A4 (en) 2001-03-14
CZ300402B6 (cs) 2009-05-13
CN1151166C (zh) 2004-05-26
PL347070A1 (en) 2002-03-11
AU747096B2 (en) 2002-05-09
NO20011634D0 (no) 2001-03-30
ATE222920T1 (de) 2002-09-15
CN100396692C (zh) 2008-06-25
EA200100407A1 (ru) 2001-10-22
DE69902624T2 (de) 2003-04-03
PL199434B1 (pl) 2008-09-30
KR100475008B1 (ko) 2005-03-08
US6458946B1 (en) 2002-10-01
DE69902624D1 (de) 2002-10-02
JP3247685B2 (ja) 2002-01-21
CN1321163A (zh) 2001-11-07
WO2000020430A1 (fr) 2000-04-13
HUP0103754A2 (hu) 2002-04-29
AU747096C (en) 2003-01-23
BR9914453A (pt) 2001-05-22
KR20020013471A (ko) 2002-02-20
HUP0103754A3 (en) 2003-01-28
EP1043329A1 (en) 2000-10-11

Similar Documents

Publication Publication Date Title
SK283729B6 (sk) Kryštály P1, P4-di(uridín-5')-tetrafosfátu alebo kryštály jeho soli, spôsob ich výroby, kryštály tetrasodnej soli P1, P4-di(uridín-5')-tetrafosfátu a kryštály jej hydrátov
AU767136B2 (en) Dinucleotide crystals
ZA200102683B (en) Crystal of diuridine tetraphosphate or salt thereof and method for preparing the same, and method for producing said compound.
JP3964809B2 (ja) ジヌクレオチドの製造法
JPS6327491A (ja) ヒポキサンチン及びその誘導体とグアニン及びその誘導体との相互分離方法
PL206867B1 (pl) Sposób wytwarzania P1,P4-di(urydyno-5'-)czterofosforanu

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20191001